enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
adakveo
novartis europharm limited - crizanlizumab - anemia, célula falciforme - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
kesimpta
novartis ireland ltd - ofatumumab - esclerose múltipla remitente-recorrente envio - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
trileptal 150 mg comprimido revestido por película
novartis farma - produtos farmacêuticos, s.a. - oxcarbazepina - comprimido revestido por película - 150 mg - oxcarbazepina 150 mg - oxcarbazepine - n/a - duração do tratamento: longa duração
femara 2.5 mg comprimido revestido por película
novartis farma - produtos farmacêuticos, s.a. - letrozol - comprimido revestido por película - 2.5 mg - letrozol 2.5 mg - letrozole - n/a - duração do tratamento: longa duração
trileptal 600 mg comprimido revestido por película
novartis farma - produtos farmacêuticos, s.a. - oxcarbazepina - comprimido revestido por película - 600 mg - oxcarbazepina 600 mg - oxcarbazepine - n/a - duração do tratamento: longa duração
trileptal 600 mg comprimido revestido por película
novartis farma - produtos farmacêuticos, s.a. - oxcarbazepina - comprimido revestido por película - 600 mg - oxcarbazepina 600 mg - oxcarbazepine - n/a - duração do tratamento: longa duração